LEXICON PHARMACEUTICALS, INC. LXRX

Rank #2441 · Nasdaq · $0.6B market cap

Audited by Ernst & Young LLP, no going-concern flag in the latest filing.

Score

18.4

P/E

-3.6

P/B

4.32

ROE

-121.4%

Op. Margin

-14265.0%

Debt Ratio

104%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆

Weak

P/E -3.6x, P/B 4.32x. Ranks in the top 76% of the universe.

Profitability ★☆☆☆☆

Poor

ROE -121.4%. Ranks in the top 97% of the universe.

Safety ★★★☆☆

Average

Debt ratio 104%. Ranks in the top 41% of the universe.

Growth ★★★★★

Excellent

Revenue growth of 766.2% year over year. Ranks in the top 1% of the universe.

Growth is the relative strength · Valuation is the relative weakness (relative to this universe).

FY	Revenue	Op. Income	Net Income	Equity	Op. Margin%	Debt%
2011	$0.0B	$-0.1B	$-0.1B	$0.2B	-840.7	49
2012	$0.0B	$-0.1B	$-0.1B	$0.3B	-1950.2	45
2013	$0.0B	$-0.1B	$-0.1B	$0.2B	-6170.6	43
2014	$0.0B	$-0.1B	$-0.1B	$0.3B	-9955.5	35
2015	$0.0B	$-0.1B	$-0.1B	$0.3B	-4607.2	70
2016	$0.0B	$-0.1B	$-0.1B	$0.2B	-439.2	215
2017	$0.1B	$0.0B	$-0.0B	$0.3B	1.1	112
2018	$0.1B	$-0.1B	$-0.1B	$0.3B	-160.5	129
2019	$0.0B	$-0.0B	$-0.1B	$0.1B	-199.2	20
2023	$0.0B	$-0.1B	$-0.1B	$0.1B	-29224.8	66
2024	$0.0B	$-0.1B	$-0.1B	$0.1B	-72489.2	146
2025	$0.0B	$-0.2B	$-0.2B	$0.1B	-14265.0	104